Pacific Biosciences
PACB
246 hedge funds and large institutions have $4.83B invested in Pacific Biosciences in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 97 increasing their positions, 77 reducing their positions, and 39 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 77
7.93% more ownership
Funds ownership: 87.04% → 94.96% (+7.9%)
6% less funds holding
Funds holding: 262 → 246 (-16)
20% less capital invested
Capital invested by funds: $6.03B → $4.83B (-$1.2B)
33% less call options, than puts
Call options by funds: $31.8M | Put options by funds: $47.5M
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
36% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$121M |
| 2 |
CC
Casdin Capital
New York
|
+$88.6M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$77.5M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$66.5M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$66.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$50.5M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$44.5M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$34.1M |
| 4 |
Two Sigma Investments
New York
|
-$17.5M |
| 5 |
Renaissance Technologies
New York
|
-$16.2M |
PACB Hedge Fund Activity: Q3 2021 in Review
246 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2021, worth a combined $4.83B — down 20% from $6.03B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of PACB and 25 opened new positions — a net loss of 14 holders — while 77 trimmed existing stakes and 97 added.
The largest buyer was William Blair Investment Management, opening a new position worth an estimated $121M. The largest seller was SB Management, cutting an estimated $50.5M.
- 246 institutional investors held Pacific Biosciences (PACB) as of Q3 2021, down from 262 in Q2 2021.
- Funds reported $4.83B of Pacific Biosciences stock for Q3 2021, down 20% quarter-over-quarter.
- 25 funds opened new Pacific Biosciences positions in Q3 2021 and 39 closed out, a net change of -14 holders.
- The largest Pacific Biosciences buyer in Q3 2021 was William Blair Investment Management, an estimated $121M added.
- The largest Pacific Biosciences seller in Q3 2021 was SB Management, an estimated $50.5M sold.
Based on aggregated 13F filings for Q3 2021.